The Lancet Oncology 'Under Review': What Each Status Means

Before the paper reaches external reviewers, a Lancet handling editor at The Lancet Oncology evaluates whether the practice-changing and global-oncology relevance warrants Lancet Oncology's selective editorial slots. Roughly 85 percent of submissions are rejected at this stage. A desk rejection most often means the handling editor concluded that the work would fit better at a sister Lancet title (eClinicalMedicine for broader open-access, Lancet Regional Health titles for regional focus) or that the global-oncology audience appeal is uncertain.

The Lancet editorial office checks format compliance: manuscript with figures embedded, supplementary information separate, reporting checklists where applicable (CONSORT for clinical trials, STROBE for observational oncology studies, REMARK for tumor-marker prognostic studies, PRISMA for systematic reviews), cover letter directed to the editor, conflict-of-interest declarations, ethics-statement documentation, IRB approvals, trial-registration documentation (Lancet requires registered clinical trials), and statistical analysis plan for clinical-trial submissions.

The handling editor reads the paper and evaluates editorial triage for practice-changing and global-oncology relevance. Lancet's editorial guidance explicitly cites these criteria.

In parallel with the handling editor's primary read, ambiguous-fit papers are discussed at the Lancet editor meeting where peer handling editors at sister Lancet titles weigh in on whether the paper would fit better at The Lancet Oncology, eClinicalMedicine, or Lancet Regional Health. This editorial-team discussion runs alongside the desk-screen and adds 3 to 5 days to the timeline that is invisible to the author in the portal.

Lancet handling editors at The Lancet Oncology invite 3 clinical or subject-based experts plus 1 statistical reviewer. The 4-reviewer model is distinct from most journals' 2 to 3 reviewer model. The recruitment window can take 7 to 14 days because clinical-oncology reviewers with topic-matched expertise and statistical reviewers are scarce.

Once reviewers agree to review, the typical Lancet Oncology peer-review cycle contributes to Lancet's 36-day median submission-to-decision-after-review target. Reviewer comments are sent to authors anonymously, unless peer reviewers wish to have their names shared. Reviewers are asked to evaluate practice-changing impact, global-oncology relevance, methodological rigor (including trial design and statistical analysis), and reproducibility. Reviewer reports for Lancet Oncology tend to be thorough; 2000 to 4000 word reports are typical for primary research papers.

After reports return, the handling editor synthesizes them. If extensive revisions are required, the revised manuscript may be shared with peer reviewers for further comment. Total submission-to-acceptance averages 64 days per Lancet Oncology editorial guidance. The decision to publish remains with the editor.

• Rejection within 1 to 5 days: Administrative issue or immediate scope mismatch.

• Rejection within 1 to 3 weeks: Handling editor desk rejection. Most rejections happen here per the 31-day median first decision.

• Still Under Review after 3 weeks: Strong signal. Paper passed the steepest Lancet filter.

• Still Under Review after 8 weeks: Reviewer-recruitment or reviewer-report delay. A polite inquiry via the submission portal is appropriate.

• Status changes to "Reports Received": Reports are in; expect a decision within 1 to 2 weeks.

This is the most common anxiety we hear from Lancet Oncology authors during the active editorial window. The honest answer: no, 5 weeks at Under Review puts you right at Lancet Oncology's 36-day submission-to-decision-after-review median. Reports may already be in editorial synthesis with the handling editor preparing a recommendation. Most reviewer-driven delays come from reviewer-recruitment timing for the 4-reviewer assembly (3 clinical/subject + 1 statistical) rather than slow reviews.

If the portal still says Under Review at the 8-week mark, the most likely explanation is that one of the assigned reviewers asked for an extension and the handling editor granted it. This is normal practice at Lancet.

During the 5-to-8-week window, the useful distinction is whether the editor needs new information. A short Editorial Manager note is reasonable for a trial-registration correction, ethics update, related-paper disclosure, data-sharing correction, meeting embargo issue, or fast-track context that changed after submission. A general timeline request is better held until week 8 because the most likely bottleneck is reviewer assembly or statistical-review synthesis.

If your Lancet Oncology paper is rejected after review, the natural cascade depends on what the reviewers and handling editor cited:

eClinicalMedicine is the most natural Lancet cascade for clinical-oncology papers with strong evidence but narrower global-oncology framing. Lancet supports manuscript-transfer within the Lancet family with reviewer reports preserved. The transfer process takes 5 to 10 days.

Lancet Regional Health (Americas, Europe, Western Pacific, Southeast Asia, Africa) is the Lancet cascade for regional-focused oncology papers where the regional health-systems framing fits better than the global-oncology Lancet Oncology bar.

JAMA Oncology is a JAMA Network cascade option for clinical-oncology papers where the JAMA Network reach is preferred. JAMA Network operates independently from Lancet; reports do not transfer.

Annals of Oncology is the ESMO cascade option for European-oncology-focused work where the European clinical framing is stronger than global health.

Lancet asks reviewers at The Lancet Oncology to evaluate four things specifically. The table below maps each to actionable preparation.

In our pre-submission work with Lancet Oncology manuscripts, three patterns generate the most consistent reviewer concerns we see at The Lancet Oncology. The recurring issue is not only whether the trial, cohort, or oncology analysis is well run. It is whether the abstract, Research in Context, and statistical package make the same global-oncology claim before reviewers need to reconstruct it.

High-income-country framing flagged for global-oncology fit. When the introduction frames the work around high-income-country treatment patterns without global-oncology generalization, Lancet reviewers consistently flag global-relevance concerns. The strongest manuscripts frame around global-health-oncology contexts.

Check your global-oncology framing →

Statistical analysis plan under-documented. When the pre-specified statistical analysis plan is thin or post-hoc analyses are not clearly distinguished from pre-specified analyses, the Lancet statistical reviewer consistently requests expanded methods documentation. The 4-reviewer assembly (3 clinical + 1 statistical) means statistical scrutiny is independent of clinical-relevance review.

Check your statistical methods and SAP alignment →

Lancet venue mismatch flagged by handling editor. When the handling editor concludes the work is sound but the practice-changing or global-oncology framing is uncertain, transfer offers to eClinicalMedicine or Lancet Regional Health are common. Lancet editors take these transfers seriously.

Check your Lancet Oncology versus Lancet family route →

We have reviewed 50+ manuscripts targeting The Lancet Oncology, Lancet, JAMA Oncology, Annals of Oncology, and Journal of Clinical Oncology. The recurring Lancet Oncology miss is not simply clinical quality; it is that the first page does not prove why the result matters to an international oncology audience now. Papers with credible trials, strong cohorts, or useful biomarkers can still feel too local, too disease-siloed, or too statistically under-specified for the 4-reviewer assembly.

In the 100-manuscript Manusights sample across clinical-oncology and high-impact medical targets, Manusights internal analysis identifies five recurring preventable risks: global relevance framed after the results instead of in the opening, SAP and post-hoc analysis boundaries left implicit, trial-registration deviations explained late, subgroup claims stronger than the interaction evidence, and data-sharing or Research in Context language that does not match the actual contribution.

This is an internal Manusights review sample, not Lancet outcome data, so we use it to identify preventable author-side risks rather than to predict acceptance.

Source limitation: official guidance explains Lancet author rules, editorial policies, and timeline signals, but it does not show private handling-editor notes, statistical-review comments, or the reason a specific manuscript is still in Editorial Manager. That is why this page separates public status interpretation from manuscript-specific readiness signals.

The most useful Lancet Oncology preparation is a first-page and statistical-readiness audit. We check whether the abstract names the clinical decision, whether Research in Context explains what the study changes, whether the statistical package can survive independent statistical review, and whether the transfer path would be eClinicalMedicine, Lancet Regional Health, JAMA Oncology, or Annals of Oncology if the editor likes the study but not the fit.

Manusights does not train AI models on customer manuscripts; we do not train on private author files. Eligible paid manuscript reviews include the 60-day money-back guarantee, which matters for unpublished trial data and embargo-sensitive oncology work.

This page was created from Lancet Oncology's public author guidance at Thelancet source page and information-for-authors PDF, Lancet editorial documentation (31-day first decision, 36-day decision after review, 64-day acceptance, 4-reviewer model with 3 clinical + 1 statistical, fast-track 3-5 day review), and Manusights pre-submission review experience with Lancet Oncology-targeted manuscripts.

For the Lancet oncology landscape beyond The Lancet Oncology, see eClinicalMedicine (broader open-access Lancet), Lancet Regional Health titles (regional focus), and sister oncology titles (JAMA Oncology, Annals of Oncology, JCO, Cancer Discovery). The choice across these titles depends on whether the central contribution is practice-changing-global-oncology (Lancet Oncology), broader-clinical-oncology (eClinicalMedicine), regional-oncology (Lancet Regional Health), JAMA-Network-clinical (JAMA Oncology), European-clinical (Annals of Oncology), or ASCO-treatment-guideline (JCO).

Reviewers at The Lancet Oncology typically include 3 clinical or subject-based experts plus 1 statistical reviewer. The statistical reviewer reviews independently of the clinical reviewers. Preparing a response template that addresses both clinical and statistical perspectives accelerates revision rounds substantially.

For a pre-upload check of your manuscript against the Lancet Oncology practice-changing-plus-global-oncology bar before submission, our Lancet Oncology pre-submission diagnostic flags the framing weaknesses and reporting-checklist gaps most likely to surface in reviewer reports.